Glucophage

Glucophage is a prescription medication that contains the active ingredient metformin hydrochloride, a biguanide oral antidiabetic agent. It is marketed in the European Union and is supplied in tablet form, though specific strengths may vary by product. Glucophage works by decreasing hepatic glucose production and improving peripheral insulin sensitivity, helping to lower elevated blood glucose levels in patients with type 2 diabetes mellitus as part of a comprehensive treatment plan.

Glucophage is indicated for the management of type 2 diabetes mellitus, typically as part of a broader therapeutic regimen that includes diet and exercise.

- Improves glycemic control in adults with type 2 diabetes. - May be used as initial monotherapy when lifestyle changes are insufficient. - Can be combined with other oral antidiabetic agents or insulin to achieve target blood glucose levels. - May be considered in patients with overweight or obesity to aid weight management as an adjunct to lifestyle measures. - Used off‑label in some regions for polycystic ovary syndrome under medical supervision.

The safety profile of Glucophage includes a range of adverse effects that vary in frequency and severity.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, and diarrhea, which often improve with dose titration. - A metallic taste in the mouth that may be transient. - Decreased appetite or mild weight loss, particularly during the initial weeks of therapy.

Serious: - Lactic acidosis, a rare but potentially life‑threatening condition characterized by rapid breathing, muscle pain, and abdominal discomfort. - Severe hypoglycemia when Glucophage is combined with insulin or sulfonylureas, requiring careful monitoring of blood glucose. - Hepatotoxicity presenting as elevated liver enzymes or jaundice, especially in patients with pre‑existing liver disease. - Vitamin B12 deficiency with prolonged use, which may lead to anemia or peripheral neuropathy.

When prescribing Glucophage, clinicians consider several precautionary measures to minimize risk and ensure safe use.

- Assess renal function before initiation and periodically thereafter, as reduced clearance increases the risk of accumulation. - Avoid use in patients with known hypersensitivity to metformin or other biguanides. - Use with caution in individuals with hepatic impairment, heart failure, or conditions predisposing to hypoxia. - Discontinue the drug prior to any radiographic studies involving iodinated contrast agents. - Monitor for signs of lactic acidosis, especially in the elderly or those with comorbidities. - Evaluate vitamin B12 levels during long‑term therapy and supplement if deficiency is detected.

Glucophage may interact with other medicines, affecting its efficacy or increasing the risk of adverse events.

Avoid: - Iodinated contrast agents used for imaging studies; they can precipitate acute renal failure when combined with metformin. - Certain cimetidine formulations that significantly reduce metformin clearance. - Renal tubular secretion inhibitors such as probenecid, which may increase metformin plasma concentrations.

Use with caution: - Insulin and sulfonylureas, which may increase the risk of hypoglycemia. - Diuretics that can affect renal function and alter metformin levels. - Corticosteroids, which may raise blood glucose and require dose adjustments. - Alcohol excess, which can potentiate lactic acidosis. - Beta‑blockers, which can mask hypoglycemia symptoms and affect glucose control. - Thyroid hormones, which may alter glucose metabolism and require monitoring.